These findings position PLK1 inhibitors as promising therapeutic agents, particularly when combined with targeted therapies that induce STAT3 activation, including EGFR/MEK/ERK inhibitors in EGFR-mutant NSCLC. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.